93 related articles for article (PubMed ID: 15154833)
1. Unravelling calcium-release channel gating: clues from a 'hot' disease.
McCarthy TV; Mackrill JJ
Biochem J; 2004 Jun; 380(Pt 2):e1-3. PubMed ID: 15154833
[TBL] [Abstract][Full Text] [Related]
2. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease.
Lyfenko AD; Goonasekera SA; Dirksen RT
Biochem Biophys Res Commun; 2004 Oct; 322(4):1256-66. PubMed ID: 15336973
[TBL] [Abstract][Full Text] [Related]
3. Personal recollections on the discovery of the ryanodine receptors of muscle.
Fleischer S
Biochem Biophys Res Commun; 2008 Apr; 369(1):195-207. PubMed ID: 18182155
[TBL] [Abstract][Full Text] [Related]
4. Distinct mechanisms for dysfunctions of mutated ryanodine receptor isoforms.
Ogawa Y
Biochem Biophys Res Commun; 2008 Apr; 369(1):208-12. PubMed ID: 18067858
[TBL] [Abstract][Full Text] [Related]
5. Ca2+ stores regulate ryanodine receptor Ca2+ release channels via luminal and cytosolic Ca2+ sites.
Laver DR
Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):889-96. PubMed ID: 17645636
[TBL] [Abstract][Full Text] [Related]
6. The dynamics of luminal depletion and the stochastic gating of Ca2+-activated Ca2+ channels and release sites.
Huertas MA; Smith GD
J Theor Biol; 2007 May; 246(2):332-54. PubMed ID: 17286986
[TBL] [Abstract][Full Text] [Related]
7. Ryanodine receptor channelopathies.
Benkusky NA; Farrell EF; Valdivia HH
Biochem Biophys Res Commun; 2004 Oct; 322(4):1280-5. PubMed ID: 15336975
[TBL] [Abstract][Full Text] [Related]
8. Calcium-dependent inactivation and the dynamics of calcium puffs and sparks.
Groff JR; Smith GD
J Theor Biol; 2008 Aug; 253(3):483-99. PubMed ID: 18486154
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
Wehner M; Rueffert H; Koenig F; Olthoff D
Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
[TBL] [Abstract][Full Text] [Related]
10. Calcium-induced calcium release in skeletal muscle.
Endo M
Physiol Rev; 2009 Oct; 89(4):1153-76. PubMed ID: 19789379
[TBL] [Abstract][Full Text] [Related]
11. Mutations in RYR1 in malignant hyperthermia and central core disease.
Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P
Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943
[TBL] [Abstract][Full Text] [Related]
12. Current views of the molecular basis of the malignant hyperthermia syndrome.
Heffron JJ; McCarthy TV
Acta Anaesthesiol Belg; 1990; 41(2):73-8. PubMed ID: 2164742
[TBL] [Abstract][Full Text] [Related]
13. Intracellular Ca2+ dynamics in malignant hyperthermia and central core disease: established concepts, new cellular mechanisms involved.
Avila G
Cell Calcium; 2005 Feb; 37(2):121-7. PubMed ID: 15589992
[TBL] [Abstract][Full Text] [Related]
14. The dynamics of stochastic attrition viewed as an absorption time on a terminating Markov chain.
DeRemigio H; Smith GD
Cell Calcium; 2005 Aug; 38(2):73-86. PubMed ID: 16099503
[TBL] [Abstract][Full Text] [Related]
15. Control of muscle ryanodine receptor calcium release channels by proteins in the sarcoplasmic reticulum lumen.
Beard NA; Wei L; Dulhunty AF
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):340-5. PubMed ID: 19278523
[TBL] [Abstract][Full Text] [Related]
16. Toward a molecular understanding of the structure-function of ryanodine receptor Ca2+ release channels: perspectives from recombinant expression systems.
George CH; Yin CC; Lai FA
Cell Biochem Biophys; 2005; 42(2):197-222. PubMed ID: 15858232
[TBL] [Abstract][Full Text] [Related]
17. Loss of the calmodulin-dependent inhibition of the RyR1 calcium release channel upon oxidation of methionines in calmodulin.
Boschek CB; Jones TE; Smallwood HS; Squier TC; Bigelow DJ
Biochemistry; 2008 Jan; 47(1):131-42. PubMed ID: 18076146
[TBL] [Abstract][Full Text] [Related]
18. Peptide probe study of the role of interaction between the cytoplasmic and transmembrane domains of the ryanodine receptor in the channel regulation mechanism.
Hamada T; Bannister ML; Ikemoto N
Biochemistry; 2007 Apr; 46(14):4272-9. PubMed ID: 17361990
[TBL] [Abstract][Full Text] [Related]
19. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
[TBL] [Abstract][Full Text] [Related]
20. Ryanodine receptors as pharmacological targets for heart disease.
Santonastasi M; Wehrens XH
Acta Pharmacol Sin; 2007 Jul; 28(7):937-44. PubMed ID: 17588328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
